Medigen Vaccine Biologics Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 12.58 million compared to TWD 0.933 million a year ago. Net loss was TWD 307.8 million compared to TWD 178.77 million a year ago. Basic loss per share from continuing operations was TWD 0.9711 compared to TWD 0.5665 a year ago.
For the six months, sales was TWD 339.22 million compared to TWD 4.08 million a year ago. Net loss was TWD 448.17 million compared to TWD 335.67 million a year ago. Basic loss per share from continuing operations was TWD 1.4162 compared to TWD 1.0723 a year ago.